EJNMMI Research

Table 3 Biodistribution (1 MBq/0.3 or 3.0 nmol) of ¹⁷⁷ Lu-DOTA-PEG _5k -Lys-BN analogue in nude mice bearing PC-3 tumours

From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with ¹⁷⁷Lu-DOTA-bombesin analogues

	¹⁷⁷Lu-DOTA-PEG _5k-Lys-BN
	1 h p.i.		24 h p.i.
Tissue	0.3 nmol	3.0 nmol	0.3 nmol	3.0 nmol
Blood	0.51 ± 0.09	0.77 ± 0.11*	0.02 ± 0.00	0.02 ± 0.00
Heart	0.22 ± 0.05	0.31 ± 0.09	0.04 ± 0.01	0.05 ± 0.01
Lung	0.92 ± 0.59	2.03 ± 1.64	0.44 ± 0.32	0.58 ± 0.36
Spleen	0.45 ± 0.11	0.39 ± 0.05	0.40 ± 0.06	0.21 ± 0.04
Kidneys	3.11 ± 0.42	3.92 ± 0.59	1.59 ± 0.42	2.12 ± 0.21
Pancreas	4.65 ± 0.18**	1.45 ± 0.18	3.72 ± 0.98*	0.90 ± 0.26
Stomach	0.42 ± 0.09	0.89 ± 0.65	0.16 ± 0.03	0.14 ± 0.10
Small intestine	0.55 ± 0.02	0.78 ± 0.39	0.20 ± 0.04*	0.10 ± 0.02
Colon	0.79 ± 0.14	0.59 ± 0.10	0.31 ± 0.08*	0.11 ± 0.03
Liver	0.50 ± 0.06	0.64 ± 0.07	0.51 ± 0.05	0.46 ± 0.02
Muscle	0.17 ± 0.03	0.20 ± 0.05	0.02 ± 0.01	0.02 ± 0.00
Bone	0.21 ± 0.03	0.31 ± 0.03	0.23 ± 0.03	0.22 ± 0.03
Tumour	2.06 ± 0.41*	1.47 ± 0.42	1.14 ± 0.10	0.66 ± 0.26
Tumour-to-blood	4.08 ± 0.54	1.89 ± 0.42	62.46 ± 3.58	36.24 ± 13.73
Tumour-to-liver	4.11 ± 0.67	2.28 ± 0.60	2.78 ± 0.21	1.47 ± 0.56
Tumour-to-kidney	0.67 ± 0.14	0.38 ± 0.13	0.62 ± 0.07	0.33 ± 0.16
Tumour-to-muscle	12.26 ± 4.01	7.20 ± 0.90	55.89 ± 32.86	27.27 ± 11.92
Tumour-to-pancreas	0.44 ± 0.08	1.01 ± 0.23	0.28 ± 0.08	0.62 ± 0.22

*P < 0.05.^; **P < 0.001. Data in percentage of injected dose per gram of tissue (%ID/g), expressed as mean ± SD at 1 and 24 h p.i. (n = 3).

Back to article page